Adaptimmune therapeutics plc (ADAP)
Income statement / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15
Revenue

0

-

1,873

42,428

-

59,505

62,296

48,689

43,172

37,833

42,099

17,330

14,137

14,198

9,693

12,225

14,680

14,490

0

0

0

Operating expenses
Research and development

96,746

97,501

99,576

93,443

94,556

98,269

100,988

101,538

94,505

87,388

79,087

70,663

67,928

63,789

63,561

56,804

48,352

39,852

0

0

0

General and administrative

40,879

43,391

43,478

43,027

44,170

43,601

41,607

39,428

35,847

31,106

28,629

25,942

24,404

23,208

22,377

21,356

20,670

17,762

0

0

0

Total operating expenses

137,625

140,892

143,054

136,470

138,726

141,870

142,595

140,966

130,352

118,494

107,716

96,605

92,332

86,997

85,938

78,160

69,022

57,614

0

0

0

Operating loss

-135,742

-139,770

-141,181

-94,042

-87,417

-82,365

-80,299

-92,277

-87,180

-80,661

-65,617

-79,275

-78,195

-72,799

-76,245

-65,935

-54,342

-43,124

0

0

0

Interest income

2,550

2,772

3,368

3,359

3,142

2,849

2,584

2,683

2,649

2,230

1,722

1,306

1,091

1,110

1,093

1,039

936

787

0

0

0

Other income, net

-4,418

75

-5,532

-8,072

-17,201

-15,501

-9,037

-3,186

15,444

8,744

6,663

3,000

383

1,002

2,610

4,522

413

2,967

0

0

0

Total other income (expense), net

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Loss before income taxes

-137,610

-136,923

-143,345

-98,755

-101,476

-95,017

-86,752

-92,780

-69,087

-69,687

-57,232

-74,969

-76,721

-70,687

-72,542

-60,374

-52,993

-39,370

0

0

0

Income tax expense

310

242

289

335

372

497

192

284

347

451

1,057

936

1,064

892

381

297

151

143

0

0

0

Net loss attributable to ordinary shareholders

-137,920

-137,165

-143,634

-99,090

-101,848

-95,514

0

0

0

-

-

-

-

-

-

-

-

-39,513

0

0

0

Deemed dividend on convertible preferred shares

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

Net loss attributable to ordinary shareholders

-

-

-

-

-

-

-

-

-

-70,138

-58,289

-75,905

-77,785

-71,579

-72,923

-60,671

-55,373

-48,176

0

0

0

Net loss per ordinary share - Basic and diluted
Earnings Per Share, Basic

-

-

-0.06

-

-

-

0.01

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Earnings Per Share, Diluted

-

-

-0.06

-

-

-

0.01

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Basic and diluted (in dollars per share)

-0.04

-

-

-0.07

-0.04

-

-

-0.08

-0.04

-

-

-0.04

-0.05

-0.04

-0.04

-0.05

-0.04

-0.04

-0.01

-0.05

-0.05

Weighted average shares outstanding:
Weighted Average Number of Shares Outstanding, Basic

-

-

630,866

-

-

-

582,004

-

-

-

561,239

-

-

-

-

-

-

-

-

-

-

Weighted Average Number of Shares Outstanding, Diluted

-

-

630,866

-

-

-

621,764

-

-

-

561,239

-

-

-

-

-

-

-

-

-

-

Basic and diluted (in shares)

739,753

-

-

629,355

627,945

-

-

565,197

562,381

-

-

556,776

428,961

424,720

424,711

424,711

424,711

424,711

424,711

316,559

181,370

Development revenue
Revenue

-

-

0

0

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

License revenue
Revenue

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-